Megace News
GTXI: Additional Positive Data from Ph III Trial of Tremifene ... - Trading Markets (press release)
... in the Phase III ADT clinical trial experiencing six or more hot flashes per day at baseline and not being treated with megestrol acetate (Megace(R)), ...
GTXI: Additional Positive Data from Ph III Trial of Tremifene ... - Trading Markets (press release)
... in the Phase III ADT clinical trial experiencing six or more hot flashes per day at baseline and not being treated with megestrol acetate (Megace(R)), ...
GTx Announces Additional Top Line Phase III Data Demonstrating ... - Business Wire (press release)
... ADT clinical trial experiencing six or more hot flashes per day at baseline and not being treated with megestrol acetate (Megace ® ), toremifene citrate ...
GTXI: Additional Positive Data from Ph III Trial of Tremifene ... - Trading Markets (press release)
... in the Phase III ADT clinical trial experiencing six or more hot flashes per day at baseline and not being treated with megestrol acetate (Megace(R)), ...
GTx Announces Additional Top Line Phase III Data Demonstrating ... - Business Wire (press release)
... ADT clinical trial experiencing six or more hot flashes per day at baseline and not being treated with megestrol acetate (Megace ® ), toremifene citrate ...
Par Pharmaceutical Reports Third-Quarter 2007 Results - Earthtimes
This impact was offset by increased sales of higher margin products such as propranolol ER and Megace ES, lower inventory write-offs and reduced sales on ...
Par Pharmaceutical Reports Third-Quarter 2007 Results - FOX News
This impact was offset by increased sales of higher margin products such as propranolol ER and Megace ES, lower inventory write-offs and reduced sales on ...
Par Pharmaceutical Reports Third-Quarter 2007 Results - FOX News
This impact was offset by increased sales of higher margin products such as propranolol ER and Megace ES, lower inventory write-offs and reduced sales on ...
Menopausal? How To Cope With Hot Flashes - NBC 11.com
More-conventional studies have been done on treatments like synthetic high-dose progestin pills (Megace), used to prevent recurrence of endometrial cancer, ...
Elan Announces the Johnson & Johnson Pharmaceutical Research ... - Business Wire (press release)
Megace® is a registered trademark owned by Bristol-Myers Squibb Company licensed to Par Pharmaceutical, Inc. Rapamune® is a registered trademark owned by ...
Megace RSS Feed